The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Antimicrobial bacteriophage-derived proteins and therapeutic applications
Open accessAbstract
Antibiotics have the remarkable power to control bacterial infections. Unfortunately, widespread use, whether regarded as prudent or not, has favored the emergence and persistence of antibiotic resistant strains of human pathogenic bacteria, resulting in a global health threat. Bacteriophages (phages) are parasites that invade the cells of virtually all known bacteria. Phages reproduce by utilizing the host cell's machinery to replicate viral proteins and genomic material, generally damaging and killing the cell in the process. Thus, phage can be exploited therapeutically as bacteriolytic agents against bacteria. Furthermore, understanding of the molecular processes involved in the viral life cycle, particularly the entry and cell lysis steps, has led to the development of viral proteins as antibacterial agents. Here we review the current preclinical state of using phage-derived endolysins, virion-associated peptidoglycan hydrolases, polysaccharide depolymerases, and holins for the treatment of bacterial infection. The scope of this review is a focus on the viral proteins that have been assessed for protective effects against human pathogenic bacteria in animal models of infection and disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430
Torchilin, V. P. (2008) · Peptide Science · doi:10.1002/bip.20989 · Cited by 283
Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics
Rodríguez-Rubio, L., Martínez, B., Donovan, D. M., Rodríguez, A., & García, P. (2013) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2012.723675 · Cited by 173
Self-citation
Cited by
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Lin, D. M., Koskella, B., & Lin, H. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.162 · Cited by 1,135
A century of the phage: past, present and future
Salmond, G. P. C., & Fineran, P. C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3564 · Cited by 823
Biotechnological applications of bacteriophages: State of the art
Harada, L. K., Silva, E. C., Campos, W. F., Del Fiol, F. S., Vila, M., Dąbrowska, K., Krylov, V. N., & Balcão, V. M. (2018) · Microbiological Research · doi:10.1016/j.micres.2018.04.007 · Cited by 318
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Luong, T., Salabarria, A.-C., & Roach, D. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.014 · Cited by 266
Self-citationGreen biologics: the algal chloroplast as a platform for making biopharmaceuticals
Taunt, H. N., Stoffels, L., & Purton, S. (2018) · Bioengineered · doi:10.1080/21655979.2017.1377867 · Cited by 81
Metadata
- Authors
- Roach, D. R., & Donovan, D. M.
- Venue
- Bacteriophage
- Publisher
- Informa UK Limited
- Published
- 2015-06-23
- Volume
- 5
- Issue
- 3
- Pages
- e1062590
- ISSN
- 2159-7073 (ISSN-L)
- 2159-7081
- OpenAlex
- W2154984047
- Cited by
- 245
- References
- 3
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimicrobial bacteriophage-derived proteins and therapeutic applications. https://app.cochat.ai/papers/10.1080/21597081.2015.1062590
- The paper
- Roach, D. R., & Donovan, D. M. (2015). Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. https://doi.org/10.1080/21597081.2015.1062590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.